Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 9,115 matching trials from the live ClinicalTrials.gov search.
Filters: Tampa, Florida Clear all
Completed Phase 1 Interventional

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

NCT05479812
View directory record Official record
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
WTX-124, pembrolizumab
Drug
Lead sponsor
Werewolf Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

NCT02581930
View directory record Official record
Conditions
Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

NCT04856865
View directory record Official record
Conditions
Food Allergy
Interventions
Low dose ADP101, High dose ADP101, Pooled Placebo
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

NCT00992836
View directory record Official record
Conditions
HIV Infections, H1N1 Influenza Virus
Interventions
Influenza A (H1N1) 2009 monovalent vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 31, 2026, 2:24 PM EDT
Completed No phase listed Observational

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
assessment of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
3,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
451
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 31, 2026, 2:24 PM EDT
Completed No phase listed Observational

Traumatic Brain Injury Among Homeless Veterans

NCT01120054
View directory record Official record
Conditions
Traumatic Brain Injury, Homelessness
Interventions
Not listed
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 89 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Denver, Colorado • Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

NCT02163694
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
56
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

Talc in Treating Patients With Malignant Pleural Effusion

NCT00002622
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Talc
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
224
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 174 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 31, 2026, 2:24 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

NCT02775851
View directory record Official record
Conditions
Desmoplastic Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Positron Emission Tomography, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
280
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 199 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 2:24 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

NCT01272037
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
Interventions
Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
5,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1435
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NCT00784719
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
CP-690,550, Cyclosporine, CP-690,550 Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

NCT02745392
View directory record Official record
Conditions
Acute Migraine
Interventions
ZP-Zolmitriptan, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 4 Interventional Results available

A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine

NCT01516892
View directory record Official record
Conditions
Migraine Disorders
Interventions
onabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
21
States / cities
Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT03569371
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 31, 2026, 2:24 PM EDT
Completed No phase listed Observational

Validation of Brain Function Assessment Algorithm for mTBI/Concussion in College Athletes

NCT02957461
View directory record Official record
Conditions
Brain Injuries, Traumatic, Concussion, Mild, Concussion, Brain, Concussion, Severe, Concussion, Intermediate
Interventions
BrainScope Ahead 200iD
Device
Lead sponsor
BrainScope Company, Inc.
Industry
Eligibility
18 Years to 25 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Fayetteville, Arkansas • Storrs, Connecticut • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 31, 2026, 2:24 PM EDT
Terminated Not applicable Interventional

Humeral Compression/Distraction Device

NCT02861495
View directory record Official record
Conditions
Humeral Fractures
Interventions
Humeral Compression/Distraction (CD) Nail
Device
Lead sponsor
Florida Orthopaedic Institute
Network
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 2 Interventional

Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

NCT00131261
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PXD101, Dexamethasone
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
West Hollywood, California • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

NCT02258542
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
100
States / cities
Andalusia, Alabama • Birmingham, Alabama • Scottsboro, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Not applicable Interventional Results available

Evaluation of ACUITY™ X4 Quadripolar Coronary Venous Leads and RELIANCE™ 4-FRONT Defibrillation Leads

NCT02071173
View directory record Official record
Conditions
Cardiac Resynchronization Therapy
Interventions
ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
96
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 85 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

NCT03580369
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01019694
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
55
States / cities
Jasper, Alabama • Mobile, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Oct 31, 2026, 2:24 PM EDT
Recruiting Phase 1 Interventional

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

NCT07064122
View directory record Official record
Conditions
Haematologic Neoplasms
Interventions
AZD2962
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 31, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme

NCT00002545
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, low-LET photon therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
243
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 186 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 31, 2026, 2:24 PM EDT